Protalix BioTherapeutics, Inc.: gross profit

What this measure means

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Exact concept: us-gaap:GrossProfit. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2009-01-01 to 2017-12-31. The SEC response was captured on 2026-09-20.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Related financial histories

• Protalix BioTherapeutics, Inc.: total assets
• Protalix BioTherapeutics, Inc.: total liabilities
• Protalix BioTherapeutics, Inc.: stockholders equity
• Protalix BioTherapeutics, Inc.: cash and cash equivalents
• Protalix BioTherapeutics, Inc.: net income or loss
• Protalix BioTherapeutics, Inc.: operating cash flow
• Protalix BioTherapeutics, Inc.: capital expenditure payments
• Protalix BioTherapeutics, Inc.: revenue
• Protalix BioTherapeutics, Inc.: financing cash flow
• Protalix BioTherapeutics, Inc.: investing cash flow
• Protalix BioTherapeutics, Inc.: retained earnings or deficit
• Protalix BioTherapeutics, Inc.: basic weighted-average shares
• Protalix BioTherapeutics, Inc.: diluted weighted-average shares
• Protalix BioTherapeutics, Inc.: basic earnings per share
• Protalix BioTherapeutics, Inc.: diluted earnings per share
• Protalix BioTherapeutics, Inc.: income tax expense or benefit
• Protalix BioTherapeutics, Inc.: net property, plant and equipment
• Protalix BioTherapeutics, Inc.: share-based compensation expense
• Protalix BioTherapeutics, Inc.: operating income or loss
• Protalix BioTherapeutics, Inc.: current assets
• Protalix BioTherapeutics, Inc.: interest expense
• Protalix BioTherapeutics, Inc.: current liabilities
• Protalix BioTherapeutics, Inc.: current accounts payable
• Protalix BioTherapeutics, Inc.: net current accounts receivable
• Protalix BioTherapeutics, Inc.: net inventory
• Protalix BioTherapeutics, Inc.: cost of revenue
• Protalix BioTherapeutics, Inc.: selling, general and administrative expense
• Protalix BioTherapeutics, Inc.: research and development expense

Inspect the source

Entity

Protalix BioTherapeutics, Inc. / CIK 0001006281

Captured

2026-09-20T05:12:00.706Z

SEC response SHA-256

5022eb9c9008f3ac21090b4bd34c0341e843ccbd807493dfa2a9e5fc19632a16

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001006281.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))